US trial go-ahead for Thoratec's CABG (coronary artery bypass graft) graft:
This article was originally published in Clinica
Thoratec Laboratories has received permission from the US FDA to begin a clinical trial of its Aria coronary artery bypass graft (CABG) under an investigational device exemption. The AEGIS/US (AlternativE Graft Investigational Study) trial will assess the prosthetic graft, which incorporates the company's proprietary biomaterial Thoralon, in bypass patients who have too few or no suitable vessels of their own. Pleasanton, California-based Thoratec said it was the first company to gain FDA approval to begin US clinical trials for a prosthetic aorta-to-coronary artery bypass graft for such patients. Trials of the graft have been underway in Canada since late last year.
You may also be interested in...
New medicines under evaluation at the European Medicines Agency.
Discussions on the shape of health care have moved from “reimagining” to the next stage: building and executing on the vision. That is the thrust of EY’s NextWave Report: New Horizons 2019. Additionally, for medtechs seeking business continuum, “duality” is now a preoccupying thought.
The idea that public corporations have obligations that extend beyond the fiduciary responsibility to shareholders will be the dominant measure of responsible business behavior in the coming decade. Uncertainty about the extent of these commitments – commonly referenced as the environmental, social and governance (ESG) agenda – has produced equally variable responses from companies in the health care business.